Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705809 | 1.00 | OPRD1 (0.50) | OPRD1KCNH2SIGMAR1SLC18A3PRCP | |
| SCHEMBL11781458 | 0.91 | OPRD1 (0.46) | OPRD1KCNH2SIGMAR1PRCPDRD2 | |
| SCHEMBL30508374 | 0.88 | SIGMAR1 (0.46) | OPRD1KCNH2SIGMAR1PRCPOPRM1 | |
| SCHEMBL11782034 | 0.88 | SIGMAR1 (0.46) | OPRD1KCNH2SIGMAR1PRCPOPRM1 | |
| SCHEMBL11686154 | 0.88 | PRCP (0.43) | OPRD1KCNH2SIGMAR1PRCP | |
| SCHEMBL11870107 | 0.88 | SIGMAR1 (0.43) | OPRD1KCNH2SIGMAR1PRCP | |
| SCHEMBL11853705 | 0.85 | SIGMAR1 (0.49) | OPRD1KCNH2SIGMAR1PRCP | |
| SCHEMBL12175500 | 0.84 | PRCP (0.54) | OPRD1KCNH2SIGMAR1PRCP | |
| Bromide SCHEMBL11735141 | 0.84 | OPRD1 (0.43) | OPRD1KCNH2SIGMAR1PRCP | |
| SCHEMBL11783954 | 0.83 | DRD2 (0.41) | OPRD1KCNH2SIGMAR1SLC18A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3959475-A | ANTIDEPRESSANT, TRANQUILIZER, ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1976-05-25 | — | — | US | claimed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-4024263-A | ANALGESIC, ANTICONVULSANT, ANTIDEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3996354-A | 1,3-Dihydro-1'-dimethylphosphinylalkyl-3-phenylspiro(isobenzofuran)s | AMERICAN HOECHST CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3980786-A | 1,3-Dihydro-3-phenyl-1'-(2-propynyl)spiro[isobenzofuran]s | AMERICAN HOECHST CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
| US-3980787-A | DIURETIC AND ANTIHYPERTENSIVE AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
| US-3959475-A | ANTIDEPRESSANT, TRANQUILIZER, ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | OPRD1 6/4885KCNH2 149/4885SIGMAR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.